Immatics Publishes Phase 1 Presentation on IMA203CD8 Cell Therapy in Solid Tumors

Bitget2026/10/23 11:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immatics published an ESMO presentation reporting Phase 1 results for its investigational PRAME-directed T-cell therapy IMA203CD8 in solid tumors.
Objective response rate reached 51% among 90 evaluable patients; confirmed objective response rate was 41%.
Higher-dose treatment in 20 patients with gynecologic cancers yielded a 60% objective response rate; confirmed responses reached 55%.
Responses remained ongoing beyond 2.5 years across indications.
Dose-limiting toxicities occurred in four of 98 patients; the maximum tolerated dose was not reached at 12.5 billion cells.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immatics Publishes Phase 1 Presentation on IMA203CD8 Cell Therapy in Solid Tumors

You may also like

Crypto prices